Replies to post #2404 on Acadia Pharmaceuticals Inc. (ACAD)

[IanFromSI]

The market doesn't seem to appreciate the nasty side effect profile of the off label anti-psychotics being used to treat AD Psychosis.

Modest improvement without those side effects should significantly add to Nuplazid sales, including off label usage.

It will be interesting to see what ACAD reports for 1Q17 usage next April.